Trade RenovoRx, Inc. - RNXT CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.10 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Prev. Close* | 1.26 |
Open* | 1.33 |
1-Year Change* | -55.81% |
Day's Range* | 1.3 - 1.33 |
52 wk Range | 0.53-5.75 |
Average Volume (10 days) | 74.69K |
Average Volume (3 months) | 1.78M |
Market Cap | 11.23M |
P/E Ratio | -100.00K |
Shares Outstanding | 10.69M |
Revenue | N/A |
EPS | -0.95 |
Dividend (Yield %) | N/A |
Beta | -100.00K |
Next Earnings Date | Feb 29, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Mar 18, 2024 | 1.32 | -0.01 | -0.75% | 1.33 | 1.36 | 1.30 |
Mar 15, 2024 | 1.26 | 0.03 | 2.44% | 1.23 | 1.29 | 1.19 |
Mar 14, 2024 | 1.27 | -0.08 | -5.93% | 1.35 | 1.47 | 1.27 |
Mar 13, 2024 | 1.63 | -0.04 | -2.40% | 1.67 | 1.80 | 1.63 |
Mar 12, 2024 | 1.63 | 0.05 | 3.16% | 1.58 | 1.63 | 1.58 |
Mar 11, 2024 | 1.67 | -0.02 | -1.18% | 1.69 | 1.69 | 1.62 |
Mar 8, 2024 | 1.70 | 0.00 | 0.00% | 1.70 | 1.74 | 1.70 |
Mar 7, 2024 | 1.67 | 0.02 | 1.21% | 1.65 | 1.67 | 1.64 |
Mar 6, 2024 | 1.67 | 0.01 | 0.60% | 1.66 | 1.67 | 1.57 |
Mar 5, 2024 | 1.64 | 0.02 | 1.23% | 1.62 | 1.65 | 1.62 |
Mar 4, 2024 | 1.62 | -0.03 | -1.82% | 1.65 | 1.75 | 1.62 |
Mar 1, 2024 | 1.69 | 0.12 | 7.64% | 1.57 | 1.76 | 1.57 |
Feb 29, 2024 | 1.69 | 0.08 | 4.97% | 1.61 | 1.78 | 1.57 |
Feb 28, 2024 | 1.55 | 0.27 | 21.09% | 1.28 | 1.61 | 1.28 |
Feb 27, 2024 | 1.33 | -0.04 | -2.92% | 1.37 | 1.37 | 1.24 |
Feb 26, 2024 | 1.29 | -0.06 | -4.44% | 1.35 | 1.41 | 1.28 |
Feb 23, 2024 | 1.36 | 0.02 | 1.49% | 1.34 | 1.36 | 1.31 |
Feb 22, 2024 | 1.31 | -0.01 | -0.76% | 1.32 | 1.34 | 1.27 |
Feb 21, 2024 | 1.31 | -0.03 | -2.24% | 1.34 | 1.34 | 1.23 |
Feb 20, 2024 | 1.33 | -0.04 | -2.92% | 1.37 | 1.40 | 1.30 |
RenovoRx, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Tuesday, March 19, 2024 | ||
Time (UTC) 12:30 | Country US
| Event Q4 2023 RenovoRx Inc Earnings Release Q4 2023 RenovoRx Inc Earnings ReleaseForecast -Previous - |
Time (UTC) 17:00 | Country US
| Event RenovoRx Inc at Roth Conference RenovoRx Inc at Roth ConferenceForecast -Previous - |
Monday, May 13, 2024 | ||
Time (UTC) 12:30 | Country US
| Event Q1 2024 RenovoRx Inc Earnings Release Q1 2024 RenovoRx Inc Earnings ReleaseForecast -Previous - |
Friday, June 7, 2024 | ||
Time (UTC) 16:00 | Country US
| Event RenovoRx Inc Annual Shareholders Meeting RenovoRx Inc Annual Shareholders MeetingForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | |
---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 |
Total Operating Expense | 9.95 | 5.609 | 3.204 | 3.896 |
Selling/General/Admin. Expenses, Total | 5.649 | 2.632 | 0.818 | 0.899 |
Research & Development | 4.301 | 3.039 | 2.386 | 2.997 |
Operating Income | -9.95 | -5.609 | -3.204 | -3.896 |
Interest Income (Expense), Net Non-Operating | 0.057 | -0.834 | -0.587 | 0.063 |
Other, Net | 0.004 | 0.119 | -0.007 | -0.006 |
Net Income Before Taxes | -9.889 | -6.324 | -3.798 | -3.839 |
Net Income After Taxes | -9.889 | -6.324 | -3.798 | -3.839 |
Net Income Before Extra. Items | -9.889 | -6.324 | -3.798 | -3.839 |
Net Income | -9.889 | -6.324 | -3.798 | -3.839 |
Income Available to Common Excl. Extra. Items | -9.889 | -6.324 | -3.798 | -3.839 |
Income Available to Common Incl. Extra. Items | -9.889 | -6.324 | -3.798 | -3.839 |
Diluted Net Income | -9.889 | -6.324 | -3.798 | -3.839 |
Diluted Weighted Average Shares | 9.05173 | 5.217 | 8.38437 | 8.38437 |
Diluted EPS Excluding Extraordinary Items | -1.0925 | -1.21219 | -0.45299 | -0.45788 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | |
Diluted Normalized EPS | -1.0925 | -1.22408 | -0.45299 | -0.45788 |
Unusual Expense (Income) | 0 | -0.062 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Total Operating Expense | 3.375 | 3.261 | 2.17 | 2.161 | 2.614 |
Selling/General/Admin. Expenses, Total | 1.45 | 1.923 | 1.394 | 1.315 | 1.224 |
Research & Development | 1.925 | 1.338 | 0.776 | 0.846 | 1.39 |
Unusual Expense (Income) | 0 | 0 | 0 | ||
Operating Income | -3.375 | -3.261 | -2.17 | -2.161 | -2.614 |
Interest Income (Expense), Net Non-Operating | 0.05 | 0.004 | 0.014 | 0.022 | 0.02 |
Other, Net | 0.998 | 0 | 0 | 0.003 | 0 |
Net Income Before Taxes | -2.327 | -3.257 | -2.156 | -2.136 | -2.594 |
Net Income After Taxes | -2.327 | -3.257 | -2.156 | -2.136 | -2.594 |
Net Income Before Extra. Items | -2.327 | -3.257 | -2.156 | -2.136 | -2.594 |
Net Income | -2.327 | -3.257 | -2.156 | -2.136 | -2.594 |
Income Available to Common Excl. Extra. Items | -2.327 | -3.257 | -2.156 | -2.136 | -2.594 |
Income Available to Common Incl. Extra. Items | -2.327 | -3.257 | -2.156 | -2.136 | -2.594 |
Diluted Net Income | -2.327 | -3.257 | -2.156 | -2.136 | -2.594 |
Diluted Weighted Average Shares | 10.6552 | 9.08999 | 9.08898 | 9.06751 | 9.05719 |
Diluted EPS Excluding Extraordinary Items | -0.21839 | -0.35831 | -0.23721 | -0.23557 | -0.2864 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.21839 | -0.35831 | -0.23721 | -0.23557 | -0.2864 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | |
---|---|---|---|---|
Total Current Assets | 7.265 | 16.281 | 1.91 | 2.266 |
Cash and Short Term Investments | 6.44 | 15.192 | 1.795 | 2.104 |
Cash & Equivalents | 4.391 | 15.192 | 1.795 | 2.104 |
Prepaid Expenses | 0.825 | 1.089 | 0.115 | 0.142 |
Other Current Assets, Total | 0 | 0.02 | ||
Total Assets | 7.265 | 16.287 | 1.914 | 2.27 |
Other Long Term Assets, Total | 0.004 | 0.004 | ||
Total Current Liabilities | 1.102 | 0.938 | 4.096 | 0.805 |
Accounts Payable | 0.534 | 0.525 | 0.162 | 0.538 |
Accrued Expenses | 0.568 | 0.413 | 0.311 | 0.232 |
Notes Payable/Short Term Debt | 0 | 0 | 2.65 | 0 |
Current Port. of LT Debt/Capital Leases | 0 | 0.117 | 0 | |
Other Current Liabilities, Total | 0 | 0.856 | 0.035 | |
Total Liabilities | 1.102 | 0.938 | 4.119 | 0.805 |
Total Long Term Debt | 0 | 0 | 0.023 | 0 |
Long Term Debt | 0 | 0.023 | 0 | |
Total Equity | 6.163 | 15.349 | -2.205 | 1.465 |
Redeemable Preferred Stock | 0 | 0 | 12.451 | 12.391 |
Common Stock | 0.001 | 0.001 | 0.001 | 0.001 |
Additional Paid-In Capital | 37.318 | 36.632 | 0.303 | 0.235 |
Retained Earnings (Accumulated Deficit) | -31.173 | -21.284 | -14.96 | -11.162 |
Total Liabilities & Shareholders’ Equity | 7.265 | 16.287 | 1.914 | 2.27 |
Total Common Shares Outstanding | 9.0977 | 8.93399 | 8.38437 | 8.38437 |
Property/Plant/Equipment, Total - Net | 0 | 0.006 | ||
Short Term Investments | 2.049 | |||
Other Equity, Total | 0.017 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 3.519 | 6.314 | 4.561 | 7.265 | 9.25 |
Cash and Short Term Investments | 3.226 | 5.954 | 3.723 | 6.44 | 8.114 |
Cash & Equivalents | 3.226 | 5.954 | 3.723 | 4.391 | 3.093 |
Prepaid Expenses | 0.252 | 0.324 | 0.592 | 0.825 | 1.136 |
Total Assets | 3.519 | 6.314 | 4.561 | 7.265 | 9.25 |
Other Long Term Assets, Total | |||||
Total Current Liabilities | 1.605 | 1.699 | 1.305 | 1.102 | 1.102 |
Accounts Payable | 0.35 | 0.872 | 0.828 | 0.534 | 0.538 |
Accrued Expenses | 1.255 | 0.827 | 0.477 | 0.568 | 0.564 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | |||||
Other Current Liabilities, Total | |||||
Total Liabilities | 3.513 | 5.126 | 1.305 | 1.102 | 1.102 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Long Term Debt | |||||
Total Equity | 0.006 | 1.188 | 3.256 | 6.163 | 8.148 |
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 |
Additional Paid-In Capital | 38.183 | 37.944 | 37.685 | 37.318 | 37.151 |
Retained Earnings (Accumulated Deficit) | -38.178 | -36.757 | -34.43 | -31.173 | -29.017 |
Total Liabilities & Shareholders’ Equity | 3.519 | 6.314 | 4.561 | 7.265 | 9.25 |
Total Common Shares Outstanding | 10.6931 | 10.6931 | 9.13125 | 9.0977 | 9.07226 |
Property/Plant/Equipment, Total - Net | 0 | 0 | |||
Short Term Investments | 0 | 0 | 0 | 2.049 | 5.021 |
Other Equity, Total | 0 | 0 | 0 | 0.017 | 0.013 |
Other Current Assets, Total | 0.041 | 0.036 | 0.246 | ||
Other Liabilities, Total | 1.908 | 3.427 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | |
---|---|---|---|---|
Net income/Starting Line | -9.889 | -6.324 | -3.798 | -3.839 |
Cash From Operating Activities | -8.811 | -5.916 | -3.528 | -3.35 |
Non-Cash Items | 0.65 | 0.673 | 0.539 | 0.046 |
Changes in Working Capital | 0.428 | -0.265 | -0.269 | 0.443 |
Cash From Investing Activities | -2.032 | -0.015 | 0 | -0.001 |
Other Investing Cash Flow Items, Total | -2.032 | 0 | -0.001 | |
Cash From Financing Activities | 0.042 | 19.328 | 3.199 | 0 |
Financing Cash Flow Items | 0 | 0.003 | 0 | |
Issuance (Retirement) of Stock, Net | 0.042 | 17.351 | 0.018 | 0 |
Issuance (Retirement) of Debt, Net | 0 | 1.977 | 3.178 | 0 |
Net Change in Cash | -10.801 | 13.397 | -0.329 | -3.351 |
Capital Expenditures | 0 | -0.015 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -3.257 | -9.889 | -7.733 | -5.597 | -3.003 |
Cash From Operating Activities | -2.706 | -8.811 | -7.13 | -4.458 | -2.097 |
Non-Cash Items | 0.115 | 0.65 | 0.486 | 0.343 | 0.171 |
Changes in Working Capital | 0.436 | 0.428 | 0.117 | 0.796 | 0.735 |
Cash From Financing Activities | 0.006 | 0.042 | 0.039 | 0.035 | 0.026 |
Issuance (Retirement) of Stock, Net | 0.006 | 0.042 | 0.039 | 0.035 | 0.026 |
Net Change in Cash | -0.668 | -10.801 | -12.099 | -12.423 | -2.071 |
Cash From Investing Activities | 2.032 | -2.032 | -5.008 | -8 | |
Capital Expenditures | 0 | 0 | 0 | ||
Financing Cash Flow Items | |||||
Issuance (Retirement) of Debt, Net | 0 | 0 | 0 | ||
Other Investing Cash Flow Items, Total | 2.032 | -2.032 | -5.008 | -8 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Bank of the West | Bank and Trust | 9.118 | 975000 | 0 | 2022-12-31 | |
Najmabadi Family Trust | Corporation | 9.118 | 975000 | 0 | 2023-04-15 | |
Boston Scientific Corporation | Corporation | 5.0871 | 543971 | 0 | 2023-04-15 | |
Bagai (Shaun R.) | Individual Investor | 2.3525 | 251557 | 0 | 2023-04-15 | LOW |
Nixon Peabody Financial Advisors LLC | Investment Advisor | 0.9087 | 97165 | 0 | 2023-06-30 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 0.5189 | 55483 | 10290 | 2023-06-30 | LOW |
Charles Schwab Investment Management, Inc. | Investment Advisor | 0.4604 | 49232 | 0 | 2023-09-30 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.3937 | 42100 | 0 | 2023-06-30 | LOW |
Marton (Laurence) | Individual Investor | 0.2379 | 25438 | 0 | 2023-04-15 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.1519 | 16244 | -97 | 2023-09-30 | LOW |
Level Four Advisory Services, LLC | Investment Advisor | 0.1403 | 15000 | 5000 | 2023-06-30 | MED |
Affinity Capital Advisors, LLC | Investment Advisor | 0.1242 | 13279 | 0 | 2023-09-30 | LOW |
Susquehanna International Group, LLP | Investment Advisor | 0.1156 | 12363 | 12363 | 2023-06-30 | MED |
Kamran Najmabadi UEO | Individual Investor | 0.0935 | 10000 | 10000 | 2023-04-15 | |
Tower Research Capital LLC | Hedge Fund | 0.0816 | 8721 | 5120 | 2023-06-30 | HIGH |
Agah (Ramtin M.D.) | Individual Investor | 0.0606 | 6477 | 0 | 2023-04-15 | |
Nelms (Angela Gill) | Individual Investor | 0.0103 | 1100 | 1100 | 2023-10-03 | |
Parametric Portfolio Associates LLC | Investment Advisor | 0.0016 | 176 | 0 | 2023-06-30 | LOW |
Wells Fargo Bank, N.A. | Bank and Trust | 0.0005 | 49 | 7 | 2023-06-30 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
RenovoRx, Inc. Company profile
About RenovoRx Inc
RenovoRx, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for the local treatment of solid tumors. The Company's lead product candidate RenovoGem. Its other product candidate include Renovo Trans-Arterial Micro-Perfusion (RenovoTAMP), and RenovoCath delivery system. RenovoGem, is a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath. Its therapy platform, RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP) is focused on optimizing drug concentration in solid tumors using small molecule chemotherapeutics that enable physicians to isolate segments of the vascular anatomy closest to tumors and force chemotherapy across the blood vessel wall to bathe these difficult-to-reach tumors in chemotherapy.
Financial summary
BRIEF: For the nine months ended 30 September 2021, RenovoRx Inc revenues was not reported. Net loss totaled to $4M.
Industry: | Medical Equipment, Supplies & Distribution (NEC) |
333 W Santa Clara St Ste 900
SAN JOSE
CALIFORNIA 95110
US
Income Statement
- Annual
- Quarterly
News
Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024Higher CPI leaves traders unfazed as US equities continue to build momentum
The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.
12:42, 15 March 2024Four reasons why Bitcoin is surging to record highs
Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.
10:18, 14 March 2024China’s National People’s Congress: The markets have again been left wanting more
China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.
08:23, 8 March 2024Central Banks: which one will cut first?
Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut
13:14, 6 March 2024Nvidia (NVDA) confronts high expectations for Q4 results
Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.
12:13, 20 February 2024UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?
UK banks will be in the spotlight in the week ahead as the European earnings season continues
16:38, 16 February 2024People also watch
Still looking for a broker you can trust?
Join the 580.000+ traders worldwide that chose to trade with Capital.com